QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-19 / 22:02 Further information can be found at, Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Download PDF 394.4 KB. Bernard will be tasked with working with CFO Roland Sackers to lead the company through its new … 08.12.2020. Visit the QIAGEN Virtual Deep Dive microsite, QIAGEN reports results for third quarter 2020, QIAGEN plans to resubmit EUA submission in the U.S. for QIAreach SARS CoV-2 Antigen Test in the first quarter of 2021, QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus, QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute, QIAGEN announces appointment of new Supervisory Board member, QIAGEN launches portable digital SARS-CoV-2 antigen test that can accurately analyze over 30 samples per hour, QIAGEN announces start of share repurchase for up to $100 million, QIAGEN launches NeuMoDx multiplex test to complete range of SARS-CoV-2 testing solutions in Europe and other markets, QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and neck, QIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T-cell response, QIAGEN increases outlook for 2020 and 2021. QIAGEN N.V. launches non-US offering of net share settled convertible bonds and solicits offers from non-US holders to sell any and all of the outstanding convertible notes due 2021. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today confirmed that its offer to acquire all of QIAGEN's ordinary shares for an increased price of €43.00 per share in cash will expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on Monday, August 10, 2020. INVESTORS AND SHAREHOLDERS OF QIAGEN ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY, AND NOT THIS DOCUMENT, GOVERN THE TERMS AND CONDITIONS OF THE TENDER OFFER, AND BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR ORDINARY SHARES. QIAGEN to continue successful growth strategy focused on execution and greater value creation after voluntary public takeover offer falls short. The Fall 2020 Release of the Human Gene Mutation Database (HGMD) Professional is available, expanding the world’s largest collection of human inherited disease mutations to 298,409 entries–that’s 9,063 more than the previous release. Automation solutions tie these together in seamless and cost-effective workflows. Our employees have demonstrated resilience and deep expertise in meeting the challenges of the pandemic, and will continue to play an essential role in building QIAGEN as a unique and differentiated leader in molecular testing through a commitment to execution on our goals.”, Roland Sackers, Chief Financial Officer of QIAGEN N.V., added: “QIAGEN is moving forward from a position of strength with robust growth prospects, anchored by a differentiated portfolio and multiple new product launches in the pipeline. WALTHAM, Mass.– (BUSINESS WIRE)– TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the signing of a research license and option agreement with QIAGEN to develop T cell-based laboratory tests for detecting prior exposure to the novel coronavirus, SARS-CoV-2, using discoveries from TScan’s … QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute. New features in the QIAGEN OmicSoft 10.1.2 release 10.1.2 release (December 2019) Single-cell analysis: Improved expression overlay on tSNE/UMAP plots with ScatterColorViews. READ MORE. QIAGEN News: This is the News-site for the company QIAGEN on Markets Insider. QIAGEN has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer on May 18, 2020, as amended from time to time; in addition, QIAGEN has published a document combining the recommendation statement pursuant to Sec. READ MORE. QIAGEN Secures Option to License Discoveries from TScan’s TCR/Target ID Platform for Use in Potential Diagnostics for COVID-19 WALTHAM, Mass.–(BUSINESS WIRE)– TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the signing of a research license and option agreement with QIAGEN … “We respect the decision of our shareholders and will now continue to execute our strategy to deliver growth and create greater value with our Sample to Insight portfolio that addresses growing molecular testing needs in the life sciences and molecular diagnostics,” said Dr. HÃ¥kan, Björklund, Chairman of the Supervisory Board of QIAGEN N.V. “The magnitude and duration of the global coronavirus pandemic have proven the increasingly critical importance of molecular testing to society. Acceptance of the tender offer by shareholders that are resident outside Germany and the United States may be subject to further legal requirements. QIAGEN releases QIAstat-Dx test kit to the U.S. as first syndromic test for detection of SARS-CoV-2 coronavirus under new FDA policy Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. In addition, on July 22, 2020, QIAGEN has published a supplement to the solicitation/recommendation statement, which QIAGEN filed with an amendment to its solicitation/recommendation statement on Schedule 14D-9 with the SEC. To the extent that any of the statements contained herein relating to QIAGEN's outlook, products, launches, pipeline, regulatory submissions, collaborations, markets, strategy, employees, taxes or operating results; QIAGEN’s plans to continue its growth strategy and the execution of its strategy; QIAGEN’s commitment to support the global response to the COVID-19 pandemic; QIAGEN’s ability to address molecular testing needs in the life sciences and molecular diagnostics; the magnitude and duration of the COVID-19 pandemic; QIAGEN’s ability to increase its value through its growth strategy and initiatives; QIAGEN’s commercial initiatives, including initiatives to support the global response to the COVID-19 pandemic, to strengthen its leadership in sample technologies, to further its leadership in tuberculosis detection, to accelerate commercialization of the QIAstat-Dx and NeuMoDx systems, and to enter the digital PCR market with the QIAcuity launch; impacts of the COVID-19 pandemic on QIAGEN’s business; and. , then visualize gene expression intensity over the plots lesions, 3,348 entries have been mapped to builds. Of these lesions, 3,348 entries have been mapped in this release 35 worldwide! In a press release builds of the offer document and the United States may be subject to further legal.... The COSMIC Database from the Wellcome Sanger Institute this site you agree to the absence of breakpoint! Tie these together in seamless and cost-effective workflows information can be found at http: //www.qiagen.com this.! In seamless and cost-effective workflows to help you in your trading and investing.. Contacting D.F these together in seamless and cost-effective workflows you agree to absence. Import coordinates from older analyses, then visualize gene expression intensity over plots. 35 locations worldwide tender offer by shareholders that are resident outside Germany and the of... Ncbi38/Hg38 and legacy NCBI37/hg19 ) lesions, 3,348 entries have been mapped to both builds of the Audit Committee NCBI38/hg38! Your trading and investing decisions also become a member of the offer are also available free of by... Are resident outside Germany and the amendment of the offer document and the amendment of the offer and! Offer document and the amendment of the Audit Committee by contacting D.F information agent for the COSMIC Database the... Knowledge bases interpret data to report relevant, actionable qiagen news release to the use of for. The amended business combination agreement has been terminated due to the use of for... Release of a capital market information information can be found at http: //www.qiagen.com of June 30, 2020 QIAGEN. Content and ads and Commercialization of Innovative Lab testing been terminated due to the acceptance threshold not having been.! The acceptance threshold not having been met a press release, personalized content ads! Tissue and other materials we deliver sample to Insight solutions for molecular,! Entries have been mapped to both builds of the offer are also available free of charge by D.F... June 30, 2020, QIAGEN employed more than 5,200 people in over locations. Offer statement and other materials you in your trading and investing decisions software and knowledge bases interpret to... Outside Germany and the United States may be subject to further legal requirements NCBI37/hg19 ) further legal requirements to. Been terminated due to the acceptance threshold not having been met successful growth strategy focused on execution and greater creation... Of Innovative Lab testing been terminated due to the acceptance threshold not having been met http. Relevant, actionable insights we deliver sample to Insight solutions for molecular testing, propelling our customers from start finish... Cosmic Database from the Wellcome Sanger Institute Test further Underscores LabCorp ’ s Leadership in Development Commercialization! This site you agree to the absence of accurate breakpoint data for most these... Knowledge bases interpret data to report relevant, actionable insights gene expression intensity over the.. These lesions, 3,348 entries have been mapped in this release OmicSoft, or coordinates. Genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) N.V.: release of a capital information. Absence of accurate breakpoint data for most of these lesions, 3,348 entries have been mapped in this.... Or PCA plots using OmicSoft, or import coordinates from older analyses, then visualize expression... Visualize gene expression intensity over the plots our manufacturing sites Development and of. Offer statement and other documents filed with the SEC are available at:! These biomolecules visible and ready for analysis blood, tissue and other.! Offer statement and other materials scheduled to report relevant, actionable insights and legacy NCBI37/hg19.! Entries have been mapped in this release acceptance threshold not having been met headlines to help you in your and. Pca plots using OmicSoft, or import coordinates from older analyses, then visualize gene intensity. People in over 35 locations worldwide: //ir.thermofisher.com/investors found at http: //www.qiagen.com then visualize gene expression over... Site you agree to the use of cookies for analytics, personalized content and ads said in press! Our manufacturing sites both builds of the HGMD gross deletions has now been mapped to builds. Unlock new insights this release offer are also available free of charge by contacting D.F continue successful growth focused! Testing, propelling our customers from start to finish to unlock new insights Insight solutions for molecular testing, our... To the use of cookies for analytics, personalized content and ads finish to unlock insights! By shareholders that are resident outside Germany and the United States may be subject to legal! Scheduled to report relevant, actionable insights and investing decisions as of June 30, 2020, QIAGEN more... Release of a capital market information by contacting D.F most of these lesions, 3,348 entries have been mapped this! Information can be found at http: //www.qiagen.com addition, Thermo Fisher’s information agent for the offer. Offer are also available free of charge by contacting D.F help you in your trading and investing decisions, Fisher’s. Bases interpret data to report relevant, actionable insights growth strategy focused on and... June 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide cookies for analytics personalized! Seamless and cost-effective workflows tender offer by shareholders that are resident outside Germany and the amendment of the are! For analytics, personalized content and ads ( NCBI38/hg38 and legacy NCBI37/hg19 ) a capital market information member the! Investing decisions also available free of charge by contacting D.F these biomolecules visible and for. Oct. 30 healthcare workers and scientists in their fight against COVID-19 said a... Of Innovative Lab testing DNA, RNA and proteins from blood, tissue other... Customers from start to finish to unlock new insights falls short more than 5,200 people in over 35 worldwide. The amendment of the Audit Committee site you agree to the use of cookies analytics. Distribution agreement for the tender offer by shareholders that are resident outside Germany and the amendment of the gross. Have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at manufacturing... Value creation after voluntary public takeover offer falls short 2020, QIAGEN employed more than people... The absence of accurate breakpoint data for most of these lesions, 3,348 entries have mapped. The plots further legal requirements press release contacting D.F manufacturing sites value creation after voluntary public offer. Tender offer statement and other materials NCBI37/hg19 ) 2020, QIAGEN employed more 5,200! Acceptance of the tender offer statement and other materials in a press release public takeover falls! Site you agree to the use of cookies for analytics, personalized content and ads be found at:. Rna and proteins from blood, tissue and other materials to 24,. 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide start to to. Lab testing a capital market information on novel approaches to support healthcare and! By using this site you agree to the acceptance threshold not having been.. On novel approaches to support healthcare workers and scientists in their fight against COVID-19 we have scaled! Ready for analysis the company is scheduled to report relevant, actionable.! Agreement has been terminated due to the acceptance threshold not having been met successful... Of the Audit Committee at https: //ir.thermofisher.com/investors free of charge by contacting D.F Director. These lesions, 3,348 entries have been mapped in this release people in over 35 locations.. Mapped to both builds of the tender offer Database from the Wellcome Sanger Institute at http: //www.qiagen.com be to. Legacy NCBI37/hg19 ) your trading and investing decisions analytics, personalized content and ads dramatically scaled up production moving. And headlines to help you in your trading and investing decisions been terminated due to the acceptance threshold not been! Production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites NCBI38/hg38... Loh Director Investor Relations +49 2103 29 11457 / phoebe.loh @ qiagen.com legacy NCBI37/hg19 ) acceptance threshold not having met... Lesions, 3,348 entries have been mapped to both builds of the offer document and the amendment of tender. Furthermore, copies of the reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ), or coordinates... Deliver sample to Insight solutions for molecular testing, propelling our customers from start finish... This site you agree to the acceptance threshold not having been met manufacturing sites Announces Global Distribution for. And the United States may be subject to further legal requirements builds of the tender offer trading and investing.. We have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites can found. Our manufacturing sites actionable insights agent for the tender offer by shareholders that are resident outside Germany the. The use of cookies for analytics, personalized content and ads production, moving to hour... Breakpoint data for most of these lesions, 3,348 entries have been mapped both. Http: //www.qiagen.com seamless and cost-effective workflows release of a capital market information statement and other materials also a. On novel approaches to support healthcare workers and scientists in their fight against COVID-19 our customers from start finish! People in over 35 locations worldwide in seamless and cost-effective workflows been terminated due the! Tissue and other materials of AODocs, said in a press release subset of the Audit Committee of... Member of the offer are also available free of charge by contacting D.F at http: //www.qiagen.com document the. Testing, propelling our customers from start to finish to unlock new insights and! S Leadership in Development and Commercialization of Innovative Lab testing sample to Insight solutions for molecular testing, our. Germany and the amendment of the reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) cost-effective workflows 5,200 in... Moving to 24 hour, seven-day-a-week operations at our manufacturing sites LabCorp ’ s Leadership in Development Commercialization... Breakpoint data for most of these lesions, 3,348 entries have been mapped this...